SCHEMBL17330907

SCHEMBL17330907

C[C@H](Nc1ncnc2cccnc12)c1nc2cccc(Cl)c2c(=O)n1C1CCCNCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 20/20 1.00
PIK3R2 O00459 13/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17330550 0.84 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17331051 0.84 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17330902 0.83 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17330905 0.83 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17331074 0.83 PIK3CD (0.70) PIK3CDPIK3R2
SCHEMBL17330673 0.81 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17330669 0.81 PIK3CD (1.00) PIK3CDPIK3R2
SCHEMBL17338338 0.81 PIK3CD (0.68) PIK3CDPIK3R2
SCHEMBL17338336 0.81 PIK3CD (0.68) PIK3CDPIK3R2
SCHEMBL17330931 0.81 PIK3CD (1.00) PIK3CDPIK3R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3154958-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES INC (US) 2020-10-07 EP claimed
EP-3154958-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Gilead Sciences, Inc. (US) 2017-04-19 EP claimed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US claimed
WO-2015191752-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 WO claimed
EP-3154958-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES INC (US) 2020-10-07 EP disclosed
EP-3154958-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES INC (US) 2020-10-07 EP disclosed
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. (US) 2018-10-09 US disclosed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. 2015-12-17 US disclosed
WO-2015191752-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361054-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS PIK3CA, AKT3, PIK3CB PIK3CD 5/4885PIK3R2 22/4885
US-10092563-B2 Phosphatidylinositol 3-kinase inhibitors PIK3CA, AKT3, PIK3CB PIK3CD 5/4885PIK3R2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.